Addressing the media at a roundtable this morning, Vani Manja, Managing Director, Boehringer Ingelheim India said, “Boehringer Ingelheim India aspires to be amongst the top five multinational pharmaceutical companies in India over the next few years. We have been enabling access to our innovator products to patients across India and the neighbouring markets in the diabetes, cardiovascular, stroke and respiratory diseases segments. Our plan in these therapy areas is to build sustainable partnerships to ensure an ecosystem of access and care for patients. We have initiated action in that direction.”

A Tale of Two Companies – Sun Pharma’s Odyssey and Organon’s Second Act

Sun Pharma’s Odyssey and Organon’s Second Act – And...

Patient Centered Pharma – Pipe Dream or Possible?

To me, patient centricity is as fascinating a concept as it is contradictory. It is fascinating because it puts power into the hands of the patient. And it is contradictory because pharma does not like giving away power over its messages or processes. Pharma has traditionally never enjoyed interaction and has depended on ‘pushing’ messages across rather than having ‘conversations’. It probably also explains why we make do with medical reps who are not the sharpest knives in the drawer and scarcely invest in sharpening them.

A Cardiologist Recounts his Fightback from a Near Death Covid19 Infection

In the lockdown, while I was on regular OPD and ICU rounds at a COVID hospital, I started noticing some mild symptoms of the Coronavirus infection. Being in the medical field and considering the severity of the pandemic situation then, I was very careful and cautious, and observed the symptoms closely. The symptoms persisted and I had to self-quarantine until the medical test reports came. It was important for me to isolate myself from the rest of the medical team and prevent the spread of the virus. Finally, the report came: I was COVID positive! Stunned and slightly devastated; I broke the news to my family who could not believe it either. As a doctor, I could only treat, comfort and empathize with the COVID patients undergoing treatment; completely isolated from their loved ones. But now, I could actually feel the uncertainty of the situation. I was hospitalized and continued to experience body-ache during the admission. It was a stressful situation where I felt anxious and stressed about everything. My CT scan reports showed mild lung infection on the day of admission but as the cytokines storm developed, my lungs were 76 % damaged in 3-5 days and I was short of breath and my oxygen level deteriorated to less than 80. I was shifted to an ICU with high-flow oxygen and was on a BiPap machine which I had purchased a few weeks ago for the hospital and never imagined that I would be using myself one day.

Contact Us
Terms of Service
Privacy Statement

Facebook

Twitter

Youtube

Healthcare Trends

Indian Pharma: The Marketing – Field Disconnect and Its Remedy

The Anomaly Unless you learn to accept that chaos is...

The Tragic Genius of Yellapragada Subbarow

Every day, doctors worldwide prescribe methotrexate, doxycycline, and folic...

Private Equity Funds in Indian Healthcare: Who Wins? Who Loses?

The Two Headlines That Should Not Coexist Two recent news...

Gen Z Healthcare: Review of the Decoding Gen Z Report

Gen Z is not waiting to get sick. But...

Character: The Ultimate Differentiator in Healthcare and Pharma

My friend Salil Kallianpur, in his Substack post "The...

Marketing

Indian Pharma: The Marketing – Field Disconnect and Its Remedy

The Anomaly Unless you learn to accept that chaos is...

The Tragic Genius of Yellapragada Subbarow

Every day, doctors worldwide prescribe methotrexate, doxycycline, and folic...

Private Equity Funds in Indian Healthcare: Who Wins? Who Loses?

The Two Headlines That Should Not Coexist Two recent news...

Gen Z Healthcare: Review of the Decoding Gen Z Report

Gen Z is not waiting to get sick. But...

Character: The Ultimate Differentiator in Healthcare and Pharma

My friend Salil Kallianpur, in his Substack post "The...

Policies/Sales

Indian Pharma: The Marketing – Field Disconnect and Its Remedy

The Anomaly Unless you learn to accept that chaos is...

The Tragic Genius of Yellapragada Subbarow

Every day, doctors worldwide prescribe methotrexate, doxycycline, and folic...

Private Equity Funds in Indian Healthcare: Who Wins? Who Loses?

The Two Headlines That Should Not Coexist Two recent news...

Gen Z Healthcare: Review of the Decoding Gen Z Report

Gen Z is not waiting to get sick. But...

Character: The Ultimate Differentiator in Healthcare and Pharma

My friend Salil Kallianpur, in his Substack post "The...

Strategy

Indian Pharma: The Marketing – Field Disconnect and Its Remedy

The Anomaly Unless you learn to accept that chaos is...

The Tragic Genius of Yellapragada Subbarow

Every day, doctors worldwide prescribe methotrexate, doxycycline, and folic...

Private Equity Funds in Indian Healthcare: Who Wins? Who Loses?

The Two Headlines That Should Not Coexist Two recent news...

Gen Z Healthcare: Review of the Decoding Gen Z Report

Gen Z is not waiting to get sick. But...

Character: The Ultimate Differentiator in Healthcare and Pharma

My friend Salil Kallianpur, in his Substack post "The...

Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
- FFE+CEO RT
- BrandStorm
Solutions & Pricing
Partner

Hot topics

7 Transitions in Leadership for Indian Pharma Leaders

The rapid pace of change, which began in 2020...

Alok Sonig Appointed CEO of Rosemont Pharmaceuticals

Effective January 1, 2026, Rosemont Pharmaceuticals has announced the...

The Pill is Now a Commodity – Can ‘Beyond the Pill’ Models Work in India?

The pill is now a commodity that many of these companies provide at heavy discounts, making money off everything ‘beyond the pill’. Investors are betting heavily on the potential of technological innovation to transform the way healthcare is delivered. The Economic Times reported that in 2021, India recorded investments of $77 billion across 1,266 deals including 164 large deals worth $58 billion. While the money reduced in 2022, the reason wasn’t a lack of faith in this business model. Meanwhile, the pharmaceuticals industry that is most affected by this quiet but rapid change, is grappling with its entrenched culture. Its current business is so profitable that everything else pales in comparison. ‘Build, measure, learn, build again’ – a mantra of the health tech industry is alien to pharma that doesn’t learn, build or measure after launching a product. Pharma also thinks of its customers as doctors alone and does precious little to connect with patients, or caregivers. People who are not sick do not feature on their radar at all. These are cultural values that keep pharma focused on the pill and discourage thinking beyond it. A social media poll conducted by MedicinMan showed almost predictable responses. 100+ respondents who work in the pharma industry in India were quite clearly divided. 48% of them wanted to know what beyond the pill actually meant, while 23% wanted to know how to execute it. The rest felt that the ultra-competitive environment in the Indian generics market required very high share-of-voice tactics (19%), or that their customers demanded product information (9%).

Masterful Minds Make Monumental Sales Moments

In our rapidly changing world, adaptability is essential. The strategies and decisions that yielded results yesterday might not be as effective today. By actively engaging with and updating our mental models, we position ourselves to adapt swiftly to evolving circumstances. This ensures our decisions remain timely and anchored in the present.